Velibor Krstic Increases Position in Strata Critical Medical Warrants to 12.4%

On April 8, 2026, private investor Velibor Krstic filed a Schedule 13D/A reporting an increased stake in Strata Critical Medical, Inc. (SRTA). Krstic acquired 374,958 warrants in open market transactions at a weighted average price of $0.011 per warrant, bringing his total holdings to 1,139,393 warrants. This represents approximately 12.4% of the 9,166,644 public warrants outstanding. Additionally, Krstic maintains a position of 26,425 shares of Common Stock. The reporting person expressed the belief that the warrants (SRTAW) are significantly undervalued relative to the company's fundamentals, citing an Adjusted EBITDA of $14.1 million and the successful integration of Keystone Perfusion. Krstic intends to actively monitor management and the Board of Directors ahead of the May 7, 2026, warrant expiration date. He may engage in discussions regarding potential value-maximizing strategies, such as a voluntary exchange offer or amendments to the warrant agreement. The purchases were funded using personal capital totaling approximately $19,380 over the last 60 days.